Literature DB >> 31493507

Clinicopathological and prognostic implications of polo-like kinase 1 expression in colorectal cancer: A systematic review and meta-analysis.

Zihan Ran1, Wenjie Chen2, Jun Shang3, Xuemei Li4, Zhiyan Nie4, Jingcheng Yang5, Na Li6.   

Abstract

BACKGROUND: Polo-like kinase 1 (PLK1) is a potential prognostic marker in colorectal cancer (CRC). Nevertheless, the clinicopathological and prognostic roles of PLK1 in CRC are still undefined. Therefore, we performed a meta-analysis to investigate the clinicopathological and prognostic relevance of PLK1 expression in CRC patients.
METHODS: Studies published between 2003 and 2016 were selected for the meta-analysis based on an electronic literature search (PubMed, EMBASE and Chinese databases). Studies that investigated the clinicopathological and prognostic impacts of PLK1 expression in CRC patients were included for this analysis.
RESULTS: Eleven studies that enrolled 1147 CRC patients were included in our meta-analysis. The effect of PLK1 level on overall survival (OS) was reported in five studies, which included 702 patients. Ten studies investigated the clinicopathological role of PLK1 expression in CRC patients. Consequently, PLK1 overexpression was associated with poorer OS in CRC patients. Furthermore, the results revealed that higher PLK1 levels were also observed in CRC tissues compared with that of normal colorectal tissues. In addition, this meta-analysis also revealed positive correlations between PLK1 upregulation and lymph node metastasis or invasion. PLK1 overexpression was significantly correlated with advanced TNM stages and higher Dukes stages.
CONCLUSION: This meta-analysis strongly supports the hypothesis that PLK1 might serve as an important factor in evaluating the biological behavior and prognosis of CRC.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinicopathological features; Colorectal cancer; Meta-analysis; Polo-like kinase 1; Prognosis

Mesh:

Substances:

Year:  2019        PMID: 31493507     DOI: 10.1016/j.gene.2019.144097

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  6 in total

1.  Upregulation of Excision Repair Cross-Complementation Group 6-Like (ERCC6L) Promotes Tumor Growth in Hepatocellular Carcinoma.

Authors:  Guangcong Zhang; Jiamei Ma; Ju Xiong; Xiaoxi Huang; Xiangyang Han; Xiangnan Yu; Xuemei Jiang
Journal:  Dig Dis Sci       Date:  2020-04-29       Impact factor: 3.199

2.  Characterization of the Survival Influential Genes in Carcinogenesis.

Authors:  Divya Sahu; Yu-Lin Chang; Yin-Chen Lin; Chen-Ching Lin
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

Review 3.  Gene Therapy for Liver Cancers: Current Status from Basic to Clinics.

Authors:  Kenya Kamimura; Takeshi Yokoo; Hiroyuki Abe; Shuji Terai
Journal:  Cancers (Basel)       Date:  2019-11-25       Impact factor: 6.639

4.  Inhibition of the PLK1-Coupled Cell Cycle Machinery Overcomes Resistance to Oxaliplatin in Colorectal Cancer.

Authors:  Zhaoliang Yu; Peng Deng; Yufeng Chen; Shini Liu; Jinghong Chen; Zihuan Yang; Jianfeng Chen; Xinjuan Fan; Peili Wang; Zerong Cai; Yali Wang; Peishan Hu; Dezheng Lin; Rong Xiao; Yifeng Zou; Yan Huang; Qiang Yu; Ping Lan; Jing Tan; Xiaojian Wu
Journal:  Adv Sci (Weinh)       Date:  2021-10-28       Impact factor: 16.806

5.  Clinicopathological Significance of AKT1 and PLK1 Expression in Oral Squamous Cell Carcinoma.

Authors:  Er-Can Sun; Shuang-Shuang Dong; Zhi-Jun Li; Chang-Xue Li
Journal:  Dis Markers       Date:  2022-06-17       Impact factor: 3.464

6.  PLK1 as one novel target for the poor prognosis of bladder cancer: An observational study.

Authors:  Bin Liu; Ling-Bing Meng; Jian-Zhi Su; Bo Fan; Shi-Bin Zhao; Hao-Yuan Wang; Tao Li; Tian-Yi Wang; Ai-Li Zhang; Xiao-Chen Ni
Journal:  Medicine (Baltimore)       Date:  2022-09-30       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.